^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    alomfilimab (SAR445256)

    i
    Other names: SAR445256, KY1044, KY 1044
    Associations

    News

    Trials
    Company:
    Sanofi
    Drug class:
    ICOS agonist
    Related drugs:
    Associations

    News

    Trials
    30d
    Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer (clinicaltrials.gov)
    P1/2, N=222, Terminated, Kymab Limited | Active, not recruiting --> Terminated; Early discontinuation based on strategic sponsor decision not driven by any safety concerns.
    Trial termination • Combination therapy • Metastases
    |
    Tecentriq (atezolizumab) • alomfilimab (SAR445256)
    7ms
    Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer (clinicaltrials.gov)
    P1/2, N=280, Active, not recruiting, Kymab Limited | Trial completion date: Apr 2024 --> Aug 2024 | Trial primary completion date: Apr 2024 --> Aug 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Tecentriq (atezolizumab) • alomfilimab (SAR445256)
    1year
    Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer (clinicaltrials.gov)
    P1/2, N=280, Active, not recruiting, Kymab Limited | Trial completion date: Nov 2024 --> Apr 2024 | Trial primary completion date: Nov 2024 --> Apr 2024
    Trial completion date • Trial primary completion date • Combination therapy • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8) • ICOS (Inducible T Cell Costimulator) • FOXP3 (Forkhead Box P3)
    |
    FOXP3 expression
    |
    Tecentriq (atezolizumab) • alomfilimab (SAR445256)
    1year
    Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer (clinicaltrials.gov)
    P1/2, N=280, Active, not recruiting, Kymab Limited | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8) • ICOS (Inducible T Cell Costimulator) • FOXP3 (Forkhead Box P3)
    |
    FOXP3 expression
    |
    Tecentriq (atezolizumab) • alomfilimab (SAR445256)
    2years
    Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer (clinicaltrials.gov)
    P1/2, N=280, Recruiting, Kymab Limited | N=412 --> 280 | Trial completion date: May 2023 --> Nov 2024 | Trial primary completion date: May 2023 --> Nov 2024
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • IO biomarker
    |
    CD8 (cluster of differentiation 8) • ICOS (Inducible T Cell Costimulator) • FOXP3 (Forkhead Box P3)
    |
    FOXP3 expression
    |
    Tecentriq (atezolizumab) • alomfilimab (SAR445256)